title: Analysis of platelet recovery after autologous transplantation with G-CSF mobilized CD34+ cells purified from leukapheresis products.
abstract: We studied platelet recovery in relation to graft content in CFUs and CD34+ cells in 31 patients with multiple myeloma (21) or non-Hodgkin lymphoma (10) receiving marrow-ablative therapy followed by autologous transplantation with G-CSF mobilized CD34+ cells purified from leukapheresis products. Twelve patients had prolonged post-transplantation thrombopenia (> or = 14 days): their graft contents in CD34+ cells, CFU-GM and BFU-E were significantly inferior to those of patients with rapid platelet recovery. Although numbers of infused CD34+ cells and CFU-GM or BFU-E were well correlated, the graft content in CD34+ cells was the only parameter predictive of platelet recovery (r = -0.38, p = 0.04), with a threshold of 2.5 x 10(6) CD34+ cells/kg. However, because rapid platelet reconstitution was obtained for 4 of 16 patients re-infused with < 2.5 x 10(6) CD34+ cells/kg, we investigated whether the graft CFU-MK content might be a better predictor of platelet reconstitution than the CD34+ cell content. Eighteen CD34 grafts were studied for CFU-MK content: CD34 and CFU-MK contents were weakly correlated (r = 0.52, p = 0.03), but there was no correlation between numbers of infused CFU-MK and time to platelet recovery. We conclude that, for autologous CD34 grafts, CFU-MK assays, like CFU-GM or BFU-E assays, cannot be used to predict platelet recovery. A CD34+ cell content > or = 2.5 x 10(6)/kg remains the only reliable indicator of the platelet reconstitution capacity of a CD34 graft.
authors.affiliation: Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Nantes, France.
authors.forename: S
authors.initials: S
authors.lastname: Hermouet
authors.forename: A E
authors.initials: AE
authors.lastname: Niaussat
authors.forename: A
authors.initials: A
authors.lastname: Briec
authors.forename: D
authors.initials: D
authors.lastname: Pineau
authors.forename: N
authors.initials: N
authors.lastname: Robillard
authors.forename: R
authors.initials: R
authors.lastname: Bataille
authors.forename: N
authors.initials: N
authors.lastname: Milpied
authors.forename: J L
authors.initials: JL
authors.lastname: Harousseau
authors.forename: B
authors.initials: B
authors.lastname: Mahé
mesh_terms: D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000032:analysis*; D001772:Blood Cell Count; D001792:Blood Platelets / Q000166:cytology*; D001804:Blood Transfusion, Autologous; D003114:Colony-Forming Units Assay; D015672:Erythroid Precursor Cells / Q000166:cytology; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology*; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000737:chemistry / Q000276:immunology*; D006801:Humans; D007937:Leukapheresis; D008224:Lymphoma, Follicular / Q000097:blood; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood; D009504:Neutrophils / Q000166:cytology; D013921:Thrombocytopenia / Q000097:blood / Q000209:etiology; D013997:Time Factors
chemical_list: D018952:Antigens, CD34; D016179:Granulocyte Colony-Stimulating Factor